Beigene (ONC) News Today $253.62 +3.78 (+1.51%) As of 02:38 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BeiGene price target raised to $259 from $207 at BernsteinMarch 13 at 10:00 AM | markets.businessinsider.comBernstein Sticks to Their Hold Rating for BeiGene (ONC)March 13 at 2:08 AM | markets.businessinsider.comBeigene, Ltd. (NASDAQ:ONC) CEO Sells $14,596,526.70 in StockMarch 9, 2025 | americanbankingnews.comBeigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 51,921 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $261.59, for a total transaction of $13,582,014.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.March 8, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 58,590 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 58,590 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $249.13, for a total value of $14,596,526.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 8, 2025 | marketbeat.comXiaodong Wang Sells 8,146 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 8,146 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total value of $2,073,808.68. Following the sale, the insider now directly owns 5,240,882 shares of the company's stock, valued at $1,334,223,739.56. The trade was a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 7, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $2,073,808.68 in StockMarch 7, 2025 | insidertrades.comInsider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells 101,000 Shares of StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 101,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $244.30, for a total transaction of $24,674,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 6, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 101,000 SharesMarch 6, 2025 | insidertrades.comFDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk ReductionMarch 5, 2025 | finance.yahoo.comBeigene (NASDAQ:ONC) Shares Gap Up - Still a Buy?Beigene (NASDAQ:ONC) Shares Gap Up - Here's What HappenedMarch 5, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Upgraded at Bank of AmericaMarch 5, 2025 | americanbankingnews.comBeiGene, Ltd.: TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyMarch 4, 2025 | finanznachrichten.deBeiGene wins FDA nod for Tevimbra in first-line esophageal cancerMarch 4, 2025 | msn.comTEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyMarch 4, 2025 | businesswire.comBeigene (NASDAQ:ONC) Shares Gap Down After Insider SellingBeigene (NASDAQ:ONC) Shares Gap Down After Insider SellingMarch 4, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Stock Rating Upgraded by Bank of AmericaBank of America upgraded Beigene from a "neutral" rating to a "buy" rating and increased their price target for the stock from $207.00 to $320.00 in a report on Monday.March 3, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: BeiGene (ONC) and Omnicell (OMCL)March 3, 2025 | markets.businessinsider.comBeiGene (ONC) Gets a Buy from J.P. MorganMarch 3, 2025 | markets.businessinsider.comBeigene FY2026 EPS Forecast Decreased by Leerink PartnrsBeigene, Ltd. (NASDAQ:ONC - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for shares of Beigene in a research report issued on Thursday, February 27th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings oMarch 3, 2025 | marketbeat.comUS$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These ResultsMarch 2, 2025 | finance.yahoo.comWhy BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025March 2, 2025 | msn.comBeiGene price target raised to $348 from $345 at GuggenheimMarch 1, 2025 | markets.businessinsider.comBeigene (NASDAQ:ONC) Price Target Raised to $313.00 at MacquarieMacquarie increased their price objective on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday.March 1, 2025 | marketbeat.comBeiGene gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 sowie Geschäftsaktualisierungen bekanntMarch 1, 2025 | businesswire.comBeigene, Ltd. (NASDAQ:ONC) Director Sells $190,535,020.00 in StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares of the company's stock, valued at approximately $189,966,920. This represents a 50.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.March 1, 2025 | marketbeat.comBeiGene granted orphan designation for sonrotoclaxFebruary 28, 2025 | markets.businessinsider.comBeiGene (ONC) Receives a Buy from Morgan StanleyFebruary 28, 2025 | markets.businessinsider.comBeigene (NASDAQ:ONC) Issues Quarterly Earnings ResultsBeigene (NASDAQ:ONC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.February 28, 2025 | marketbeat.comThe Billionaire Baker Brothers Just Made This Big Biotech Stock MoveFebruary 28, 2025 | 247wallst.comBeigene (NASDAQ:ONC) Hits New 12-Month High - Still a Buy?Beigene (NASDAQ:ONC) Sets New 1-Year High - Time to Buy?February 28, 2025 | marketbeat.comBeiGene sees FY25 revenue $4.9B-$5.3B, consensus $4.74BFebruary 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BeiGene (ONC) and Viridian Therapeutics (VRDN)February 27, 2025 | markets.businessinsider.comBeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesFebruary 27, 2025 | businesswire.comChan Henry Lee Sells 1,202 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $258.04, for a total value of $310,164.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link.February 26, 2025 | marketbeat.comLai Wang Sells 5,000 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 5,000 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $257.23, for a total value of $1,286,150.00. Following the transaction, the insider now directly owns 920,920 shares in the company, valued at approximately $236,888,251.60. This represents a 0.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 26, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) SVP Chan Henry Lee Sells 1,202 SharesFebruary 26, 2025 | insidertrades.comBeiGene to Present at Upcoming Investor ConferencesFebruary 25, 2025 | businesswire.comBeigene (NASDAQ:ONC) Reaches New 12-Month High - Still a Buy?Beigene (NASDAQ:ONC) Hits New 1-Year High - Should You Buy?February 22, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 21,267 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 21,267 shares of Beigene stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total value of $5,105,568.69. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.February 21, 2025 | marketbeat.comXiaobin Wu Sells 30,654 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 30,654 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total transaction of $7,379,643.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.February 21, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) COO Sells $5,105,568.69 in StockFebruary 21, 2025 | insidertrades.comBeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27February 13, 2025 | businesswire.comBostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell LymphomaFebruary 11, 2025 | finance.yahoo.comLeerink Partnrs Brokers Raise Earnings Estimates for BeigeneBeigene, Ltd. (NASDAQ:ONC - Free Report) - Investment analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Beigene in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($5.5February 10, 2025 | marketbeat.com Remove Ads Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼0.180.71▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼1212▲ONC Articles Average Week Remove Ads Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News TAK News ARGX News BNTX News TEVA News GMAB News SMMT News ITCI News MRNA News VTRS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONC) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beigene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts